Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 22Other hematologic neoplasm 15CNS 5Sarcoma 4Genitourinary 4Plasma cell 3Gynecologic 3Breast 2Tumor-Agnostic 1Gastrointestinal 1Dermatologic 1

Conditions

Glioblastoma 4Astrocytoma 2Neuroblastoma 1Lymphoma, Follicular 1Glioma 1Ganglioneuroblastoma 1

Interventions

Temozolomide 165Magnetic Resonance Spectroscopy 130Radiotherapy 95Specimen Handling 80Radiosurgery 60Cyclophosphamide 55pembrolizumab 51Bevacizumab 51Nivolumab 48Radiation 47Carboplatin 34Biopsy 33Irinotecan 29Lomustine 25Etoposide 25Vincristine 23Topotecan 23Ipilimumab 23dinutuximab 21Cisplatin 21Blood Specimen Collection 21fludarabine 19Radiotherapy, Intensity-Modulated 19X-Rays 18Surgical Procedures, Operative 18abemaciclib 16Mental Status and Dementia Tests 16Granulocyte-Macrophage Colony-Stimulating Factor 16Pemetrexed 15atezolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Leukapheresis × CNS × 1 year × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT07544992 2026-05-06

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

City of Hope Medical Center

Phase 1 Recruiting
24 enrolled
CNS

Astrocytoma, Glioblastoma

NCT06186401 2026-03-16

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

University of California, San Francisco

Phase 1 Recruiting
20 enrolled
CNS

Glioblastoma

NCT03389230 2026-02-04

Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma

City of Hope Medical Center

Phase 1 Active not recruiting
29 enrolled
CNS

Glioblastoma, Glioma

NCT06815029 2025-06-26

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

City of Hope Medical Center

Phase 1 Recruiting
27 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡